Introduction
For most patients, the diagnosis of heart failure will have a similar significance to that of cancer. The prognosis of heart failure due to left ventricular dysfunction is poor, with a 5-year survival of 50% and 10-year of only 20% [1] . However failure mortality is, like cancer, related to disease severity, with a 25% 4-year mortality in Grade 2, 50% in Grade 3, and a 50% 1-year mortality in Grade 4 heart failure [1] . Moderate to severe heart failure carries mortality rates equivalent to colorectal cancer [2] . The prognosis of all grades of heart failure combined is worse than breast or prostatic cancer [3] , common malignancies that present at similar ages to heart failure but attract greater public attention and clinical care initiatives.
Heart failure also has high impact on health care costs. In Britain, 4·9% of admissions to one hospital were for heart failure, extrapolating to 100 000-120 000 admissions per year nationally [4] . Furthermore, with improved survival after acute myocardial infarction and increasingly elderly populations, the prevalence of heart failure will continue to rise.
In terms of the individual patient, the primary care physician's role might be involved in early and accurate initial diagnosis, the implementation of evidencebased treatments and, subsequently, adequate disease monitoring. In addition, primary care physicians have a role in the primary prevention of heart failure, through the early identification of potential aetiological causes and the aggressive management of identified risk factors. Unfortunately, there is evidence of doctor under-performance, possibly due to these multiple and inter-connected aspects of care. For example, there is evidence of physician misdiagnosis. Several studies have explored the validity of a clinical diagnosis of heart failure in primary care, and report high rates of misdiagnosis when patients are assessed against objective criteria [5] [6] [7] [8] . However, these data, reporting low rates of confirmed heart failure amongst patients with a diagnostic label, provide only a partial picture. Diagnostic criteria for establishing heart failure, such as those of the Working Group on Heart Failure of the European Society of Cardiology (ESC) [9] , require appropriate symptoms plus clinical signs, plus evidence of cardiac structural abnormality. Accurate diagnosis requires access to objective cardiac investigation, most notably echocardiography. The availability of such services to primary care physicians in Europe is not known.
Under-management of heart failure is a further issue, although this problem is not confined to primary care [10, 11] . The factors that influence under-treatment of heart failure have not been previously described, although limited data from Britain [12] suggests concerns over side-effects may reduce angiotensin-converting enzyme (ACE) prescribing. This study, therefore, aimed to survey a random sample of primary care physicians across six European countries regarding their perceptions of diagnostic and prescribing issues in heart failure, and to consider factors that might be associated with physician under-performance.
Methods
For the survey a structured questionnaire was developed, with expert cardiological advice, listing questions concerning: practice characteristics; the usual way a diagnosis of heart failure was established; access to investigations; names of drugs prescribed in heart failure, with estimates of the proportion of patients supplied with particular classes; and physician attitudes regarding the evidence base (in terms of benefits and risks) for treatments used. Questions were mainly categorical with options for the physicians to select, with space for other answers. A final series of questions presented two case history scenarios, with open responses. Data from these case scenarios are not reported here. In a pilot study, 14 local primary care physicians provided reliability and validity checks on the questionnaire, after which final modifications were made to the wording and structure.
The questionnaires together with an explanatory covering letter were translated into the languages of the participating European countries. The countries surveyed were France, Germany, Italy, The Netherlands and Spain. Translations were checked for accuracy by different translators. In Britain, the names of 250 primary care physicians were selected randomly from the U.K. National Database of General Practitioners. The Nivel Foundation (The Netherlands) supplied 500 randomly selected names and addresses of primary care physicians. It proved difficult to obtain lists of general practitioners in France, Germany, Italy and Spain as the professional organizations approached were either unable or unprepared to supply national lists or a random sample. Therefore, a commercial source 1 was used to provide 1050 names and addresses of primary care physicians in each country of France, Germany, Italy and Spain. A random selection of 200 primary care physicians was prepared for each of the continental European countries.
For Britain, the first mailing comprised the questionnaire together with a covering letter and a FREEPOST reply envelope. The first mailing to France, Germany, Italy, The Netherlands and Spain comprised the questionnaire and covering letter in the appropriate language together with an English version of the questionnaire and an International Business Reply Service envelope. A second mailing was made to all non-responders in each country. A third mailing was made to all U.K. non-responders.
In order to validate the accuracy of the information obtained from the address databases, follow-up telephone calls were made at a random selection of 20 non-responders in each European country. From the information obtained, the response rate was adjusted to exclude those not eligible to participate e.g. those who were retired, had left the practice, or were not primary care physicians. Statistical methods included descriptive analysis and the following tests of hypothesis:
2 tests for comparison between Britain and Continental Europe (as a five-nation grouping) for treatment effectiveness and median tests on practice size and number of heart failure patients on each country's practice list.
Results
Completed questionnaire response rate varied from 17% (France) to 56% (Britain) ( Table 1 ). There were no significant difference in responding practice type (urban suburban, rural) between Britain and other European countries, however Britain had significantly (P<0·001) larger practice list sizes. In view of the particularly poor response rates in some countries, data are only reported on all countries where purely opinion responses were requested. For all other responses, comparisons are made between Britain and Continental European countries only or combined total responses reported.
When asked to estimate the approximate adult prevalence of heart failure the majority opinion was correct at 2 per 100 (54%) ( Table 2) ; however 29% hugely underestimated the rate at 2 per 1000. The variation in the estimated rate of heart failure patients may be due to inadequate identification as only 42% of the primary care physicians questioned kept a disease register to enable them to subsequently identify heart failure patients ( Table 3) .
Methods of establishing a diagnosis and prescribing habits
Oedema and breathlessness or dyspnoea were considered the signs and symptoms most suggestive of heart failure in all countries (the five most common responses are listed in (Table 4) . Most patients were diagnosed on either symptoms alone (26%) or on symptoms plus signs (41%), with only a minority having further investigation or referral (Table 5 ). Chest X-rays and electrocardiography were the two most commonly ordered tests (Table 6 ) in all six countries. Almost all doctors claimed to prescribe loop diuretics, cardiac glycosides and ACE inhibitors in a proportion of patients with heart failure. Doctors estimated that approximately 65% of heart failure patients received loop diuretics ( Table 7 ). The next most commonly used drug class was ACE inhibitors, in a range of 47-62% of patients. Whilst between 62% and 90% of doctors (depending on country) stated that they used thiazide Primary care management of heart failure 1879 diuretics in heart failure, it was only in 14-31% of patients. There was more variation with cardiac glycosides; although most doctors use them, in Britain it was only in 16% of patients compared within 23-58% in the other countries.
The most common drugs and the usual daily maintenance dose prescribed are given in (Table 8 ). The same proprietary drug was prescribed by a majority of primary care physicians across Europe for the following classes of drugs: loop diuretics (frusemide), cardiac glycosides (digoxin), ACE inhibitors (enalapril), and beta-blockers (atenolol). Most of the primary care physicians prescribe a single dose for diuretics and beta-blockers but were more likely to prescribe a range of cardiac glycosides and ACE inhibitors ( Table 8 ). The usual perceived dose range for ACE inhibitors was below trial target doses [13, 14] .
Perceptions on treatment effectiveness and risk
Almost all the physicians believe that loop diuretics were effective in relieving symptoms in heart failure 10 20 patients (Table 9 ). Fewer were convinced of thiazide efficacy. ACE inhibitors were considered to be effective in symptom relief by an average of 80% of doctors. The vast majority (91%) of prescribing doctors believed that there was strong evidence of reduced mortality in heart failure patients when using ACE inhibitors (Table 9 ), but over half also believed their use was associated with potentially significant risks. The risks and side-effects recorded by the British respondents, are listed in Table 10 .
Discussion
The importance of collecting perceptual data from clinicians relates to hypothesis generation: how much can the observable variation in clinical practice be hypothecated on practitioners' declared attitudes regarding clinical issues? Such data are therefore important since widespread documentation of the failures of clinical practitioners to implement evidence starkly contrasts with the paucity of information on practitioner beliefs. Collecting information about physician perceptions, however, is always problematic in terms of the generalizability of responses.
In this study, as in other questionnaire surveys, limitations over the data include how the responses accord with actual clinical practice and the variable response rate. The very low response rates in some counties in this study is comparable to other European primary care surveys [15, 16] ; however this will have compromised study generalizability, particularly over the non-opinion, categorical responses. This study does, however, have the advantage of having randomly sampled the primary care physicians, rather than having selective sampled doctors by approaching individuals with a special interest in the topic area. This latter practice is the usual way that such surveys collect information on professionals [15, 16] . These data therefore incorporate the views of a randomly selected group of nearly 300 doctors around Europe.
The study provides interesting preliminary insights into some of the variations in practice around heart failure that exist across Europe. In every country surveyed, a sizeable minority of doctors underestimate the true adult prevalence of heart failure, with 32% believing it to be at least ten times less frequent than its actual prevalence. Perceptions about the 'background epidemiology' of chronic diseases are important in service practice, since they may influence the clinician's threshold of suspicion of newly presenting disease. Primary care management of heart failure 1881
In terms of heart failure diagnosis, as with other chronic diseases, the contribution primary care makes to the diagnosis is crucial in two particular areas. The first relates to the stage at which the diagnosis is established, since early diagnosis may influence ultimate prognosis. The second is the reliability of diagnosis, since misdiagnosis may lead to under-treatment, over-treatment or other inappropriate management. The potential for these practitioners to validate their existing diagnoses of heart failure is undermined by their lack of disease registers (absent in 55% of practitioners between countries). Also this lack of registers would complicate any strategies the practitioners might develop to find heart failure prospectively in patient cohorts at higher risk of the disease, such as those having suffered myocardial infarction or having existing hypertension.
The 'low tech' approach to heart failure was further evident from responses to the questions about how the physicians confirmed a diagnosis in suspected cases. A sizeable majority of doctors in every country diagnosed on symptoms and signs alone without formal investigation or referral. Practitioners in all countries consistently, and appropriately, described the most frequent signs or symptoms of heart failure as oedema or breathlessness. However, the non-specific nature of these symptoms will overlap with a number of chronic disorders, including dependant peripheral oedema and respiratory disease. Objective testing is, therefore, required in patients with suspected heart failure to both confirm the diagnosis and to guide management. The most appropriate investigation in most patients will be echocardiography, although only a minority of practices had direct open access to this test. The most commonly ordered tests, when these were arranged, were an electrocardiograph (ECG) or chest X-ray. Although a normal ECG may be a reliable test at excluding heart failure [17, 18] , the test has low sensitivity and high technical ability, with many primary care practitioners likely to miss more subtle abnormalities on ECG.
Concerns have been expressed that providing primary care physicians direct access to echocardiography would result in inappropriate utilization. However, evidence from open access endoscopy has consistently demonstrated that primary care physicians use such services appropriately [19, 20] . Furthermore, a trial of open access echocardiography considered only 12% of referrals as 'inappropriate' [21] . One potential diagnostic aid for the future, of particular relevance to primary care settings, is the assessment of patients by brain natriuretic peptide assay, although current data on brain natriuetic peptide assay validity are conflicting [22, 23] . If misdiagnosis is perceived as a problem for primary care physicians, then the appropriate response should be to enhance access to relevant diagnostic investigations [24] .
Management of heart failure
There are fewer variations in prescribing reported between countries than anticipated. Doctors report prescribing ACE inhibitors for between one-half and two-thirds of their heart failure patients, which is likely to be overestimated on the basis of small practice based audits. A comparative European study by CardioMonitor TM , recording actual prescribing by a non-random sample of primary care physicians in five of the six countries surveyed, suggests that doctors in this study over-estimated their ACE prescribing by about 50% (personal communication).
The most significant data on the physicians' management strategies related to their perceived use of ACE inhibitors. Since these are the main class of drug with demonstrated reduced mortality and improved morbidity in heart failure, their prescribing characteristics are the most noteworthy. In addition to under utilizing ACE inhibitors as a class, the physicians appeared to under-dose with ACE inhibitor in treated patients. Across continental Europe, doses of ACE inhibitors reportedly used were lower than the levels used in treatment trials in 68% to 70% of responses. In most cases, doses prescribed were half those recommended [25, 26] . Some of the factors influencing this ACE inhibitor under-use can be inferred from the physicians' views on the evidence base for ACE inhibitors. Most doctors perceive strong evidence of effectiveness, in terms of symptom relief, for most of the drugs they prescribe in heart failure, with the exception of digoxin and thiazides. However, in terms of evidence of effectiveness in reducing mortality, only the ACE inhibitors scored highly: 91% of primary care physicians in Europe understood the main treatment benefits of ACE inhibitors. These findings are important since they suggest that the under-utilization and under-treatment of patients with heart failure by ACE inhibitor is not due to lack of understanding of treatment benefits.
The questions relating to treatment risks, however, offer further insight into under-use. Fifty-one per cent of doctors in Europe perceived that ACE inhibition carry substantial risks. Furthermore, 62% consider they carry substantial side-effects in heart failure patients. These data suggest that treatment decisions by these doctors are dominated by perceptions of treatment risk rather than treatment benefit. Thus, perceptions of causing direct harm to patients appear to overcome the 'indirect harm' that might result from denying evidence-based treatment. These data are consistent with findings from studies exploring physician under-utilization of warfarin for patients with atrial fibrillation, which suggest that primary and secondary care physicians are more concerned about risks of causing haemorrhage with warfarin than avoidance of stroke. These data also support the limited qualitative data on ACE inhibitor under-use in the U.K., which indicate that concerns over renal failure and hypertension were key factors [12] . It would appear that the Hippocratic Oath 'first do not harm' may not ideally guide the modern clinician in balancing the direct benefits and risks of treatment with the indirect dis-utility of doing nothing.
One further explanation for ACE under-utilization may reside in these physicians' perceptions of the reliability of their diagnosis. If doctors perceive that a proportion of their diagnoses are not accurate, since they are established on clinical grounds, then it may be more appropriate for them to question the introduction of treatments that are considered to be more potent or to have greater risks. Access to definitive investigation might, therefore, not only improve the reliability of diagnoses, but, by enhancing certainty, the physicians may become more comfortable with prescribing treatments perceived to be associated with risks as well as benefits.
In summary, these preliminary data suggest that, across Europe, primary care physicians underestimate heart failure prevalence. The diagnosis of heart failure is mostly established on clinical grounds alone, and physicians have limited access to objective investigations of left ventricular function. In terms of treatment for heart failure, most doctors claimed to use ACE inhibitors, but in only a modest majority of patients and in lower than recommended doses. This under-usage did not appear to be related to lack of knowledge on the evidence for ACE inhibitor benefits, but appeared to be linked to exaggerated perceptions of the risks and adverse affects associated with ACE inhibitor use. If primary care physicians in Europe are to respond more appropriately to the expanding burden of heart failure, they will require better access to echocardiography together with further education on the implementation of evidence-based treatments.
European Survey of Primary Care Management of Heart Failure
There are major international variations in the treatment of common disorders in primary care. This survey aims to describe the diagnosis and management of heart failure in primary care across 6 countries. The questionnaire should take around 10 min to complete. There are no right or wrong answers to the questions therefore simply respond according to the way you usually practice. All questions will be dealt with strictly confidentially and all responses will be anonymised. We will feed back a personal copy of the results to all responders. How many patients do you have on your total list (all doctors in your practice)? How many patients on your total list have heart failure? Do you keep a disease register that would enable you to identify heart failure patients?
Diagnostic factors

YES/NO
Are you prepared to participate in an audit of your prescribing for heart failure in the second phase of this study (which will be remunerated)? YES/NO
